X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Under the agreement, Charles River will conduct a GLP toxicology study for IMP761, a first-in-class LAG-3 agonist antibody and Immutep's proprietary preclinical candidate for autoimmune diseases.
Lead Product(s): IMP761
Therapeutic Area: Immunology Product Name: IMP761
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Charles River Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 29, 2023
Details:
IMP761 is a first-in-class immunosuppressive agonist antibody to LAG-3. As a targeted immunosuppressive antibody, IMP761 has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells.
Lead Product(s): IMP761
Therapeutic Area: Immunology Product Name: IMP761
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2022
Details:
IMP761 is first-in-class immunosuppressive agonist antibody to LAG-3 has potential to address root cause of AID by specifically silencing autoimmune memory T cells that accumulate at disease site and express LAG-3.
Lead Product(s): IMP761
Therapeutic Area: Immunology Product Name: IMP761
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2022
Details:
Under the agreement, Northway has already started developing a GMP-compliant manufacturing process of IMP761 and will manufacture IMP761 in large scale bioreactors. Planning for further pre-clinical and clinical development is ongoing.
Lead Product(s): IMP761
Therapeutic Area: Immunology Product Name: IMP761
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Immutep
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 16, 2021
Details:
The claims of the patent are directed to Immutep’s pre-clinical product candidate, IMP761, and also to the use of IMP761 in the treatment of T-cell mediated inflammatory and autoimmune diseases.
Lead Product(s): IMP761
Therapeutic Area: Immunology Product Name: IMP761
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2020
Details:
Using its STEP®-mAb technology, Batavia Biosciences has developed a pharmaceutical-grade, stable CHO cell line that produces significantly high product yields of IMP761.
Lead Product(s): IMP761
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
